119-HR-5160 DC Insider Whip Count Analysis
119 · HR 5160 Stem Cell Therapeutic and Research Reauthorization Act of 2025
Bipartisan health reauthorization with clean policy and modest funding uptick cleared House Energy & Commerce: Health Subcommittee by voice vote on May 13, 2026 and the full committee 46–0 on May 21, 2026, signaling near-unanimous support. Republicans control both chambers in the 119th Congress; Senate HELP is chaired by Bill Cassidy, positioning the measure for swift consideration, likely by unanimous consent if no holds emerge. Prior reauthorizations (2015, 2021) advanced on voice or near-unanimous votes, and major patient/clinical coalitions (NMDP/Be The Match, ASTCT, ASGCT) are publicly lobbying for passage. Expect high likelihood of House and Senate passage, barring late riders or a single-senator hold. [1]U.S. House Committee Repository — E&C Health Subcommittee Markup Vote Summary (…
01 · Section
Breakdown: expected support by party and caucus
Scope: H.R. 5160 would extend the C.W. Bill Young Cell Transplantation Program and related authorities; text sets $33,009,000 annually for FY27–FY31 for 42 U.S.C. 274m and continues the National Cord Blood Inventory authorization window. Patterned as a clean, technical reauthorization. [2]Congress.gov — H.R. 5160 (Text, Introduced) — 119th Congress
- Bill status and bipartisan pedigree: introduced by Rep. Chris Smith (R‑NJ) with co-leads across the aisle (Matsui, Bilirakis, Pingree, Tenney, Mfume) and additional bipartisan cosponsors. Referred to Energy & Commerce. [3]Congress.gov — All Info - H.R.5160 (119th): Stem Cell Therapeutic and Research…
- Committee action signals: Health Subcommittee forwarded by voice vote (May 13, 2026); full E&C reported the bill 46–0 (May 21, 2026). These votes capture both conference wings on the committee. [1]U.S. House Committee Repository — E&C Health Subcommittee Markup Vote Summary (…
- House outlook: given unanimous committee support and the bill’s prior-cycle precedent of overwhelming votes, expect broad support from both parties; typical floor vehicle would be non‑controversial consideration requiring a two‑thirds vote if leadership places it under suspension. [4]U.S. Senate (Reed) — Sen. Reed: Congress Approves TRANSPLANT Act (House 415–2;…
- Senate outlook: Republicans hold a 53‑seat majority; HELP Chair Bill Cassidy (R‑LA) controls first stop, and the chamber often processes bipartisan health reauthorizations by unanimous consent absent objections. [5]U.S. Senate — U.S. Senate Party Division — 119th Congress
- Organized support: patient/clinical coalitions are engaged (NMDP/Be The Match; ASTCT; ASGCT sign‑on), which typically boosts Democratic and mainstream Republican buy‑in. [6]NMDP — NMDP applauds introduction of H.R. 5160
- Historical vote pattern: comparable reauthorizations cleared by voice/UC (2015) and 415–2 in the House with Senate voice in 2021—setting a high bipartisan baseline. [7]Congress.gov — All Info - H.R. 2820 (114th): 2015 reauthorization (House voice;…
02 · Section
Key legislators and pivotal actors
Who can move—or stall—the bill based on portfolio and leverage.
- Rep. Chris Smith (R‑NJ), sponsor and longtime program author; paired with Rep. Doris Matsui (D‑CA) on policy substance; Matsui also filed the full‑committee AINS, indicating cross‑party text alignment. Floor managers likely from E&C leadership. [3]Congress.gov — All Info - H.R.5160 (119th): Stem Cell Therapeutic and Research…
- Chair Brett Guthrie (R‑KY) and Ranking Member Frank Pallone (D‑NJ) advanced the bill through E&C; Guthrie’s markup agenda and statements frame it as a patient‑support reauth, limiting partisan wedges. [8]House Energy & Commerce Committee — Chairman Guthrie Opening Statement at Full…
- Speaker Mike Johnson controls House floor time; he was reelected Speaker on Jan. 3, 2025, with a narrow GOP majority—expectation is placement among consensus health items. [9]Clerk of the U.S. House of Representatives — House Clerk: Vote on Election of t…
- Sen. Bill Cassidy (R‑LA), HELP Chair; Sen. Bernie Sanders (I‑VT), Ranking Member—both with institutional sway over health reauthorizations; Cassidy’s chairmanship signals a GOP‑led markup or hotline path. [10]Senate HELP Committee — Cassidy seated as Chair of Senate HELP Committee (119th…
- Senate floor control: Majority Leader John Thune (R‑SD) sets timing; most bipartisan reauthorizations clear by UC unless a member objects, which would force cloture (generally 60 votes). [11]U.S. Senate — U.S. Senate: About Voting (unanimous consent; tie‑breaks; cloture)
03 · Section
Leadership influence and procedural dynamics
Process and leverage points that determine timing and final form.
- House process: Unanimous committee record positions the bill for the Suspension Calendar; that route requires two‑thirds for passage and prohibits floor amendments, insulating the bill from poison‑pill riders. [1]U.S. House Committee Repository — E&C Health Subcommittee Markup Vote Summary (…
- Senate process: Standard path is hotline/UC. Any single objection creates a time problem, requiring cloture and floor hours. With a 53‑seat GOP majority and visible bipartisan support, the votes are gettable if leaders devote time. [5]U.S. Senate — U.S. Senate Party Division — 119th Congress
- Inter‑chamber coordination: HELP could move a Senate companion (or amended text) and then swap with the House by UC. AABB and allied groups are already flagging a Senate reauth vehicle in 2026, easing bicameral alignment. [12]aabb.org
- Appropriations interface: H.R. 5160 authorizes levels for FY27–31; program dollars are ultimately set in Labor‑HHS appropriations—so keeping the bill clean avoids cross‑jurisdictional friction on the floor. [2]Congress.gov — H.R. 5160 (Text, Introduced) — 119th Congress
04 · Section
Assessment and bottom line
Likelihood of passage and confidence level, based on votes, leadership posture, and lobbying landscape.
- House: High likelihood of passage given 46–0 committee vote, bipartisan cosponsors, and fit for suspension. [13]U.S. House Committee Repository — E&C Full Committee Roll Call Vote #7 on H.R.…
- Senate: High but slightly less certain due to UC dynamics; GOP majority (53) plus bipartisan history points to smooth passage if no holds. [5]U.S. Senate — U.S. Senate Party Division — 119th Congress
- Historical anchor: 2015 cleared by voice/UC; 2021 reauth passed the House 415–2 and the Senate by voice—comparable coalition strength today. [7]Congress.gov — All Info - H.R. 2820 (114th): 2015 reauthorization (House voice;…
- Interest‑group pressure is aligned (NMDP/Be The Match; ASTCT; ASGCT), increasing political cost of an out‑of‑step ‘no’ and discouraging riders. [6]NMDP — NMDP applauds introduction of H.R. 5160
House passage probability
95%
Senate passage probability
90%
Sources cited
- [1] E&C Health Subcommittee Markup Vote Summary (May 13, 2026) U.S. House Committee Repository
- [2] H.R. 5160 (Text, Introduced) — 119th Congress Congress.gov
- [3] All Info - H.R.5160 (119th): Stem Cell Therapeutic and Research Reauthorization Act of 2025 Congress.gov
- [4] Sen. Reed: Congress Approves TRANSPLANT Act (House 415–2; Senate voice) U.S. Senate (Reed)
- [5] U.S. Senate Party Division — 119th Congress U.S. Senate
- [6] NMDP applauds introduction of H.R. 5160 NMDP
- [7] All Info - H.R. 2820 (114th): 2015 reauthorization (House voice; Senate UC) Congress.gov
- [8] Chairman Guthrie Opening Statement at Full Committee Markup (May 21, 2026) House Energy & Commerce Committee
- [9] House Clerk: Vote on Election of the Speaker (Jan. 3, 2025) Clerk of the U.S. House of Representatives
- [10] Cassidy seated as Chair of Senate HELP Committee (119th Congress) Senate HELP Committee
- [11] U.S. Senate: About Voting (unanimous consent; tie‑breaks; cloture) U.S. Senate
- [12] aabb.org
- [13] E&C Full Committee Roll Call Vote #7 on H.R. 5160 (46–0) (May 21, 2026) U.S. House Committee Repository
Discussion